English

Lineage Cell Therapeutics, Inc.

EDGAR

BTX Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2025: about USD 14.56M, using the latest reported figures. The previous period, 2024, was about USD 9.499M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1.07 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 1069000 USD Source

Operating margin

-834.71%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -8923000 USD Source
Revenue: 1069000 USD Source

Operating cash flow

-7.24 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -15322000 USD Source
Operating Cash Flow: -8078000 USD Source

Free cash flow

-7.35 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -15322000 USD Source
Operating Cash Flow: -8078000 USD Source
Capital Expenditure: 163000 USD Source
Capital Expenditure: 55000 USD Source

Cash and cash equivalents: 37.4 million USD 2026-06-30 Source
Exact value

37355000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 253 million shares 2026-06-30 Source
Exact value

252907464 shares

Reported share-count change

10.75% · 24.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

228356290 shares · 2025-06-30· Source
252907464 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 10 of 11 periods available· newest 2025-12-31
Total liabilities: 10 of 11 periods available· newest 2025-12-31
Current assets: 10 of 11 periods available· newest 2025-12-31
Current liabilities: 10 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 10 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+53.2%

Prior period

USD 9.5 million

2024-01-01 – 2024-12-31
Current period

USD 14.56 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

14556000 − 9499000 = 5057000 USD

9499000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
14556000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Lineage Cell Therapeutics, Inc. · 2025-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Year-over-year change in Revenue: 5057000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 14556000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2488479 Filing: 000119312526093992 Input fundies:Revenue: 9499000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2490215 Filing: 000119312526093992
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 44.92 million

Prior period

−USD 18.61 million

2024-01-01 – 2024-12-31
Current period

−USD 63.53 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-63533000 − -18609000 = -44924000 USD

-18609000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-63533000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Lineage Cell Therapeutics, Inc. · 2025-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Year-over-year change in Net income: -44924000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -63533000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2094943 Filing: 000119312526093992 Input fundies:NetIncome: -18609000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2096687 Filing: 000119312526093992
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 4.17 million

Prior period

−USD 23.09 million

2024-01-01 – 2024-12-31
Current period

−USD 18.92 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-18919000 − -23092000 = 4173000 USD

-23092000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-18919000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Lineage Cell Therapeutics, Inc. · 2025-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Year-over-year change in Operating cash flow: 4173000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -18919000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2165877 Filing: 000119312526093992 Input fundies:OperatingCashFlow: -23092000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2167745 Filing: 000119312526093992
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-7.6%

Prior period

USD 565,000

2024-01-01 – 2024-12-31
Current period

USD 522,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

522000 − 565000 = -43000 USD

565000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
522000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Lineage Cell Therapeutics, Inc. · 2025-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Year-over-year change in Capital expenditure: -43000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 522000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2186697 Filing: 000119312526093992 Input fundies:CapitalExpenditure: 565000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2188553 Filing: 000119312526093992
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 14.56 million 100% of revenue
Operating costs Derived USD 51.18 million 352% of revenue
Operating income −USD 36.62 million −252% of revenue
Tax, interest and other Derived USD 26.91 million 185% of revenue
Net income −USD 63.53 million −436% of revenue

Cash

Operating cash flow −USD 18.92 million −130% of revenue
Capital expenditure USD 522,000 3.6% of revenue
Free cash flow Derived −USD 19.44 million −134% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 1,096% of revenue.
2017 Operating loss: operating costs were 1,225% of revenue.
2018 Operating loss: operating costs were 938% of revenue.
2019 Operating loss: operating costs were 1,206% of revenue.
2020 Operating loss: operating costs were 1,548% of revenue.
2021 Operating loss: operating costs were 1,234% of revenue.
2022 Operating loss: operating costs were 253% of revenue.
2023 Operating loss: operating costs were 377% of revenue.
2024 Operating loss: operating costs were 326% of revenue.
2025 Operating loss: operating costs were 352% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	5923000	64890000 Derived	-58967000	-92539000 Derived	33572000	-44574000 Derived	Source 2016-01-01 – 2016-12-31: 5923000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -58967000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: 33572000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -42326000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 2248000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	3458000	42360000 Derived	-38902000	-18926000 Derived	-19976000	-31843000 Derived	Source 2017-01-01 – 2017-12-31: 3458000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -38902000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -19976000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -30517000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1326000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	4988000	46783000 Derived	-41795000	4195000 Derived	-45990000	-31438000 Derived	Source 2018-01-01 – 2018-12-31: 4988000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -41795000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -45990000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -30882000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 556000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	3515000	42391000 Derived	-38876000	-27167000 Derived	-11709000	-32387000 Derived	Source 2019-01-01 – 2019-12-31: 3515000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -38876000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -11709000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -31947000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 440000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	1826000	28273000 Derived	-26447000	-5798000 Derived	-20649000	-19817000 Derived	Source 2020-01-01 – 2020-12-31: 1826000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -26447000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -20649000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -19753000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 64000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	4341000	53552000 Derived	-49211000	-6192000 Derived	-43019000	-23901000 Derived	Source 2021-01-01 – 2021-12-31: 4341000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -49211000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -43019000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -23561000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 340000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	14703000	37223000 Derived	-22520000	3753000 Derived	-26273000	646000 Derived	Source 2022-01-01 – 2022-12-31: 14703000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -22520000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -26273000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 1059000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 413000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	8945000	33678000 Derived	-24733000	-3247000 Derived	-21486000	-29240000 Derived	Source 2023-01-01 – 2023-12-31: 8945000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -24733000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -21486000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -28566000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 674000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	9499000	30977000 Derived	-21478000	-2869000 Derived	-18609000	-23657000 Derived	Source 2024-01-01 – 2024-12-31: 9499000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -21478000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -18609000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -23092000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 565000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	14556000	51175000 Derived	-36619000	26914000 Derived	-63533000	-19441000 Derived	Source 2025-01-01 – 2025-12-31: 14556000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -36619000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -63533000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -18919000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 522000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 14.6M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	5923000	Revenue: 5923000 Open source
20172017-12-31	Revenue	3458000	Revenue: 3458000 Open source
20182018-12-31	Revenue	4988000	Revenue: 4988000 Open source
20192019-12-31	Revenue	3515000	Revenue: 3515000 Open source
20202020-12-31	Revenue	1826000	Revenue: 1826000 Open source
20212021-12-31	Revenue	4341000	Revenue: 4341000 Open source
20222022-12-31	Revenue	14703000	Revenue: 14703000 Open source
20232023-12-31	Revenue	8945000	Revenue: 8945000 Open source
20242024-12-31	Revenue	9499000	Revenue: 9499000 Open source
20252025-12-31	Revenue	14556000	Revenue: 14556000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

53.2% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	-15.8%	Revenue: 5923000 Open source Revenue: 7036000 Open source
20172017-12-31	Year over year	-41.6%	Revenue: 3458000 Open source Revenue: 5923000 Open source
20182018-12-31	Year over year	44.2%	Revenue: 4988000 Open source Revenue: 3458000 Open source
20192019-12-31	Year over year	-29.5%	Revenue: 3515000 Open source Revenue: 4988000 Open source
20202020-12-31	Year over year	-48.1%	Revenue: 1826000 Open source Revenue: 3515000 Open source
20212021-12-31	Year over year	137.7%	Revenue: 4341000 Open source Revenue: 1826000 Open source
20222022-12-31	Year over year	238.7%	Revenue: 14703000 Open source Revenue: 4341000 Open source
20232023-12-31	Year over year	-39.2%	Revenue: 8945000 Open source Revenue: 14703000 Open source
20242024-12-31	Year over year	6.2%	Revenue: 9499000 Open source Revenue: 8945000 Open source
20252025-12-31	Year over year	53.2%	Revenue: 14556000 Open source Revenue: 9499000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -251.6% 2025

Net margin -436.5% 2025

Free cash flow margin -133.6% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-995.6%	Operating Income: -58967000 Open source Revenue: 5923000 Open source
20172017-12-31	Operating margin	-1,125%	Operating Income: -38902000 Open source Revenue: 3458000 Open source
20182018-12-31	Operating margin	-837.9%	Operating Income: -41795000 Open source Revenue: 4988000 Open source
20192019-12-31	Operating margin	-1,106%	Operating Income: -38876000 Open source Revenue: 3515000 Open source
20202020-12-31	Operating margin	-1,448.4%	Operating Income: -26447000 Open source Revenue: 1826000 Open source
20212021-12-31	Operating margin	-1,133.6%	Operating Income: -49211000 Open source Revenue: 4341000 Open source
20222022-12-31	Operating margin	-153.2%	Operating Income: -22520000 Open source Revenue: 14703000 Open source
20232023-12-31	Operating margin	-276.5%	Operating Income: -24733000 Open source Revenue: 8945000 Open source
20242024-12-31	Operating margin	-226.1%	Operating Income: -21478000 Open source Revenue: 9499000 Open source
20252025-12-31	Operating margin	-251.6%	Operating Income: -36619000 Open source Revenue: 14556000 Open source
20162016-12-31	Net margin	566.8%	Net Income: 33572000 Open source Revenue: 5923000 Open source
20172017-12-31	Net margin	-577.7%	Net Income: -19976000 Open source Revenue: 3458000 Open source
20182018-12-31	Net margin	-922%	Net Income: -45990000 Open source Revenue: 4988000 Open source
20192019-12-31	Net margin	-333.1%	Net Income: -11709000 Open source Revenue: 3515000 Open source
20202020-12-31	Net margin	-1,130.8%	Net Income: -20649000 Open source Revenue: 1826000 Open source
20212021-12-31	Net margin	-991%	Net Income: -43019000 Open source Revenue: 4341000 Open source
20222022-12-31	Net margin	-178.7%	Net Income: -26273000 Open source Revenue: 14703000 Open source
20232023-12-31	Net margin	-240.2%	Net Income: -21486000 Open source Revenue: 8945000 Open source
20242024-12-31	Net margin	-195.9%	Net Income: -18609000 Open source Revenue: 9499000 Open source
20252025-12-31	Net margin	-436.5%	Net Income: -63533000 Open source Revenue: 14556000 Open source
20162016-12-31	Free cash flow margin	-752.6%	Revenue: 5923000 Open source Operating Cash Flow: -42326000 Open source Capital Expenditure: 2248000 Open source
20172017-12-31	Free cash flow margin	-920.9%	Revenue: 3458000 Open source Operating Cash Flow: -30517000 Open source Capital Expenditure: 1326000 Open source
20182018-12-31	Free cash flow margin	-630.3%	Revenue: 4988000 Open source Operating Cash Flow: -30882000 Open source Capital Expenditure: 556000 Open source
20192019-12-31	Free cash flow margin	-921.4%	Revenue: 3515000 Open source Operating Cash Flow: -31947000 Open source Capital Expenditure: 440000 Open source
20202020-12-31	Free cash flow margin	-1,085.3%	Revenue: 1826000 Open source Operating Cash Flow: -19753000 Open source Capital Expenditure: 64000 Open source
20212021-12-31	Free cash flow margin	-550.6%	Revenue: 4341000 Open source Operating Cash Flow: -23561000 Open source Capital Expenditure: 340000 Open source
20222022-12-31	Free cash flow margin	4.4%	Revenue: 14703000 Open source Operating Cash Flow: 1059000 Open source Capital Expenditure: 413000 Open source
20232023-12-31	Free cash flow margin	-326.9%	Revenue: 8945000 Open source Operating Cash Flow: -28566000 Open source Capital Expenditure: 674000 Open source
20242024-12-31	Free cash flow margin	-249%	Revenue: 9499000 Open source Operating Cash Flow: -23092000 Open source Capital Expenditure: 565000 Open source
20252025-12-31	Free cash flow margin	-133.6%	Revenue: 14556000 Open source Operating Cash Flow: -18919000 Open source Capital Expenditure: 522000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -18.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-42326000	Operating Cash Flow: -42326000 Open source
20172017-12-31	Operating cash flow	-30517000	Operating Cash Flow: -30517000 Open source
20182018-12-31	Operating cash flow	-30882000	Operating Cash Flow: -30882000 Open source
20192019-12-31	Operating cash flow	-31947000	Operating Cash Flow: -31947000 Open source
20202020-12-31	Operating cash flow	-19753000	Operating Cash Flow: -19753000 Open source
20212021-12-31	Operating cash flow	-23561000	Operating Cash Flow: -23561000 Open source
20222022-12-31	Operating cash flow	1059000	Operating Cash Flow: 1059000 Open source
20232023-12-31	Operating cash flow	-28566000	Operating Cash Flow: -28566000 Open source
20242024-12-31	Operating cash flow	-23092000	Operating Cash Flow: -23092000 Open source
20252025-12-31	Operating cash flow	-18919000	Operating Cash Flow: -18919000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -19.4M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-44574000	Operating Cash Flow: -42326000 Open source Capital Expenditure: 2248000 Open source
20172017-12-31	Free cash flow	-31843000	Operating Cash Flow: -30517000 Open source Capital Expenditure: 1326000 Open source
20182018-12-31	Free cash flow	-31438000	Operating Cash Flow: -30882000 Open source Capital Expenditure: 556000 Open source
20192019-12-31	Free cash flow	-32387000	Operating Cash Flow: -31947000 Open source Capital Expenditure: 440000 Open source
20202020-12-31	Free cash flow	-19817000	Operating Cash Flow: -19753000 Open source Capital Expenditure: 64000 Open source
20212021-12-31	Free cash flow	-23901000	Operating Cash Flow: -23561000 Open source Capital Expenditure: 340000 Open source
20222022-12-31	Free cash flow	646000	Operating Cash Flow: 1059000 Open source Capital Expenditure: 413000 Open source
20232023-12-31	Free cash flow	-29240000	Operating Cash Flow: -28566000 Open source Capital Expenditure: 674000 Open source
20242024-12-31	Free cash flow	-23657000	Operating Cash Flow: -23092000 Open source Capital Expenditure: 565000 Open source
20252025-12-31	Free cash flow	-19441000	Operating Cash Flow: -18919000 Open source Capital Expenditure: 522000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

61.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	8.5%	Total Liabilities: 12064000 Open source Total Assets: 142572000 Open source
20172017-12-31	Liabilities / assets	5.2%	Total Liabilities: 8978000 Open source Total Assets: 173241000 Open source
20182018-12-31	Liabilities / assets	9.3%	Total Liabilities: 9414000 Open source Total Assets: 101660000 Open source
20192019-12-31	Liabilities / assets	11.3%	Total Liabilities: 14231000 Open source Total Assets: 125478000 Open source
20202020-12-31	Liabilities / assets	11.9%	Total Liabilities: 12822000 Open source Total Assets: 107949000 Open source
20212021-12-31	Liabilities / assets	47.9%	Total Liabilities: 83647000 Open source Total Assets: 174545000 Open source
20222022-12-31	Liabilities / assets	41.8%	Total Liabilities: 51728000 Open source Total Assets: 123664000 Open source
20232023-12-31	Liabilities / assets	38.6%	Total Liabilities: 38996000 Open source Total Assets: 101019000 Open source
20242024-12-31	Liabilities / assets	32%	Total Liabilities: 36206000 Open source Total Assets: 113218000 Open source
20252025-12-31	Liabilities / assets	61.5%	Total Liabilities: 69238000 Open source Total Assets: 112584000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.2× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	2.9×	Current Assets: 25649000 Open source Current Liabilities: 8850000 Open source
20172017-12-31	Current assets / current liabilities	6.2×	Current Assets: 42623000 Open source Current Liabilities: 6879000 Open source
20182018-12-31	Current assets / current liabilities	5.34×	Current Assets: 36358000 Open source Current Liabilities: 6812000 Open source
20192019-12-31	Current assets / current liabilities	8.86×	Current Assets: 57519000 Open source Current Liabilities: 6494000 Open source
20202020-12-31	Current assets / current liabilities	5.66×	Current Assets: 43999000 Open source Current Liabilities: 7769000 Open source
20212021-12-31	Current assets / current liabilities	2.37×	Current Assets: 111549000 Open source Current Liabilities: 47116000 Open source
20222022-12-31	Current assets / current liabilities	3.16×	Current Assets: 60000000 Open source Current Liabilities: 18981000 Open source
20232023-12-31	Current assets / current liabilities	2.14×	Current Assets: 38441000 Open source Current Liabilities: 17960000 Open source
20242024-12-31	Current assets / current liabilities	3.65×	Current Assets: 50997000 Open source Current Liabilities: 13977000 Open source
20252025-12-31	Current assets / current liabilities	5.2×	Current Assets: 59157000 Open source Current Liabilities: 11367000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	USD 33.57 million Exact value Exact value: 33572000 USD 2016-01-01 – 2016-12-31: 33572000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lineage Cell Therapeutics, Inc. · 2016-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Net Income: 33572000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: 33572000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315218003416/btx-20171231.xml#213498 Filing: 000149315218003416 The citation records this snapshot. The page link may show a newer release later.	−USD 42.33 million Exact value Exact value: -42326000 USD 2016-01-01 – 2016-12-31: -42326000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lineage Cell Therapeutics, Inc. · 2016-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Operating Cash Flow: -42326000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -42326000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315218003416/btx-20171231.xml#230835 Filing: 000149315218003416 The citation records this snapshot. The page link may show a newer release later.	USD 2.25 million Exact value Exact value: 2248000 USD 2016-01-01 – 2016-12-31: 2248000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lineage Cell Therapeutics, Inc. · 2016-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Capital Expenditure: 2248000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2248000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315218003416/btx-20171231.xml#1092285 Filing: 000149315218003416 The citation records this snapshot. The page link may show a newer release later.	−USD 44.57 million Calculation and evidence -42326000 − 2248000 USD Exact free cash flow: -44574000 USD 2016-01-01 – 2016-12-31: -42326000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 2248000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lineage Cell Therapeutics, Inc. · 2016-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Free cash flow: -44574000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -42326000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315218003416/btx-20171231.xml#230835 Filing: 000149315218003416 Input fundies:CapitalExpenditure: 2248000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315218003416/btx-20171231.xml#1092285 Filing: 000149315218003416 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 19.98 million Exact value Exact value: -19976000 USD 2017-01-01 – 2017-12-31: -19976000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lineage Cell Therapeutics, Inc. · 2017-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Net Income: -19976000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19976000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315219003335/btx-20181231.xml#209823 Filing: 000149315219003335 The citation records this snapshot. The page link may show a newer release later.	−USD 30.52 million Exact value Exact value: -30517000 USD 2017-01-01 – 2017-12-31: -30517000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lineage Cell Therapeutics, Inc. · 2017-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Operating Cash Flow: -30517000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30517000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315219003335/btx-20181231.xml#219743 Filing: 000149315219003335 The citation records this snapshot. The page link may show a newer release later.	USD 1.33 million Exact value Exact value: 1326000 USD 2017-01-01 – 2017-12-31: 1326000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lineage Cell Therapeutics, Inc. · 2017-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Capital Expenditure: 1326000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1326000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315219003335/btx-20181231.xml#948219 Filing: 000149315219003335 The citation records this snapshot. The page link may show a newer release later.	−USD 31.84 million Calculation and evidence -30517000 − 1326000 USD Exact free cash flow: -31843000 USD 2017-01-01 – 2017-12-31: -30517000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1326000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lineage Cell Therapeutics, Inc. · 2017-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Free cash flow: -31843000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -30517000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315219003335/btx-20181231.xml#219743 Filing: 000149315219003335 Input fundies:CapitalExpenditure: 1326000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315219003335/btx-20181231.xml#948219 Filing: 000149315219003335 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 45.99 million Exact value Exact value: -45990000 USD 2018-01-01 – 2018-12-31: -45990000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lineage Cell Therapeutics, Inc. · 2018-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Net Income: -45990000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -45990000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315220003818/lctx-20191231.xml#761730 Filing: 000149315220003818 The citation records this snapshot. The page link may show a newer release later.	−USD 30.88 million Exact value Exact value: -30882000 USD 2018-01-01 – 2018-12-31: -30882000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lineage Cell Therapeutics, Inc. · 2018-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Operating Cash Flow: -30882000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30882000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315220003818/lctx-20191231.xml#766820 Filing: 000149315220003818 The citation records this snapshot. The page link may show a newer release later.	USD 556,000 Exact value Exact value: 556000 USD 2018-01-01 – 2018-12-31: 556000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lineage Cell Therapeutics, Inc. · 2018-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Capital Expenditure: 556000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 556000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315220003818/lctx-20191231.xml#937287 Filing: 000149315220003818 The citation records this snapshot. The page link may show a newer release later.	−USD 31.44 million Calculation and evidence -30882000 − 556000 USD Exact free cash flow: -31438000 USD 2018-01-01 – 2018-12-31: -30882000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 556000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lineage Cell Therapeutics, Inc. · 2018-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Free cash flow: -31438000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -30882000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315220003818/lctx-20191231.xml#766820 Filing: 000149315220003818 Input fundies:CapitalExpenditure: 556000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315220003818/lctx-20191231.xml#937287 Filing: 000149315220003818 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 11.71 million Exact value Exact value: -11709000 USD 2019-01-01 – 2019-12-31: -11709000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lineage Cell Therapeutics, Inc. · 2019-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Net Income: -11709000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11709000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k.htm#1243554 Filing: 000149315221005814 The citation records this snapshot. The page link may show a newer release later.	−USD 31.95 million Exact value Exact value: -31947000 USD 2019-01-01 – 2019-12-31: -31947000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lineage Cell Therapeutics, Inc. · 2019-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Operating Cash Flow: -31947000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31947000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k.htm#1267009 Filing: 000149315221005814 The citation records this snapshot. The page link may show a newer release later.	USD 440,000 Exact value Exact value: 440000 USD 2019-01-01 – 2019-12-31: 440000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lineage Cell Therapeutics, Inc. · 2019-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Capital Expenditure: 440000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 440000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k.htm#1272317 Filing: 000149315221005814 The citation records this snapshot. The page link may show a newer release later.	−USD 32.39 million Calculation and evidence -31947000 − 440000 USD Exact free cash flow: -32387000 USD 2019-01-01 – 2019-12-31: -31947000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 440000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lineage Cell Therapeutics, Inc. · 2019-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Free cash flow: -32387000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31947000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k.htm#1267009 Filing: 000149315221005814 Input fundies:CapitalExpenditure: 440000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k.htm#1272317 Filing: 000149315221005814 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 20.65 million Exact value Exact value: -20649000 USD 2020-01-01 – 2020-12-31: -20649000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lineage Cell Therapeutics, Inc. · 2020-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Net Income: -20649000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20649000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315222006520/form10-k.htm#1398732 Filing: 000149315222006520 The citation records this snapshot. The page link may show a newer release later.	−USD 19.75 million Exact value Exact value: -19753000 USD 2020-01-01 – 2020-12-31: -19753000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lineage Cell Therapeutics, Inc. · 2020-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Operating Cash Flow: -19753000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19753000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315222006520/form10-k.htm#1420657 Filing: 000149315222006520 The citation records this snapshot. The page link may show a newer release later.	USD 64,000 Exact value Exact value: 64000 USD 2020-01-01 – 2020-12-31: 64000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lineage Cell Therapeutics, Inc. · 2020-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Capital Expenditure: 64000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 64000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315222006520/form10-k.htm#1425088 Filing: 000149315222006520 The citation records this snapshot. The page link may show a newer release later.	−USD 19.82 million Calculation and evidence -19753000 − 64000 USD Exact free cash flow: -19817000 USD 2020-01-01 – 2020-12-31: -19753000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 64000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lineage Cell Therapeutics, Inc. · 2020-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Free cash flow: -19817000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19753000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315222006520/form10-k.htm#1420657 Filing: 000149315222006520 Input fundies:CapitalExpenditure: 64000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315222006520/form10-k.htm#1425088 Filing: 000149315222006520 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 43.02 million Exact value Exact value: -43019000 USD 2021-01-01 – 2021-12-31: -43019000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lineage Cell Therapeutics, Inc. · 2021-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Net Income: -43019000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -43019000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315223007129/form10-k.htm#1473354 Filing: 000149315223007129 The citation records this snapshot. The page link may show a newer release later.	−USD 23.56 million Exact value Exact value: -23561000 USD 2021-01-01 – 2021-12-31: -23561000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lineage Cell Therapeutics, Inc. · 2021-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Operating Cash Flow: -23561000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23561000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315223007129/form10-k.htm#1491290 Filing: 000149315223007129 The citation records this snapshot. The page link may show a newer release later.	USD 340,000 Exact value Exact value: 340000 USD 2021-01-01 – 2021-12-31: 340000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lineage Cell Therapeutics, Inc. · 2021-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Capital Expenditure: 340000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 340000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315223007129/form10-k.htm#1494781 Filing: 000149315223007129 The citation records this snapshot. The page link may show a newer release later.	−USD 23.9 million Calculation and evidence -23561000 − 340000 USD Exact free cash flow: -23901000 USD 2021-01-01 – 2021-12-31: -23561000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 340000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lineage Cell Therapeutics, Inc. · 2021-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Free cash flow: -23901000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23561000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315223007129/form10-k.htm#1491290 Filing: 000149315223007129 Input fundies:CapitalExpenditure: 340000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000149315223007129/form10-k.htm#1494781 Filing: 000149315223007129 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 26.27 million Exact value Exact value: -26273000 USD 2022-01-01 – 2022-12-31: -26273000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lineage Cell Therapeutics, Inc. · 2022-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Net Income: -26273000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26273000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000095017024027988/lctx-20231231.htm#1549554 Filing: 000095017024027988 The citation records this snapshot. The page link may show a newer release later.	USD 1.06 million Exact value Exact value: 1059000 USD 2022-01-01 – 2022-12-31: 1059000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lineage Cell Therapeutics, Inc. · 2022-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Operating Cash Flow: 1059000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1059000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000095017024027988/lctx-20231231.htm#1600600 Filing: 000095017024027988 The citation records this snapshot. The page link may show a newer release later.	USD 413,000 Exact value Exact value: 413000 USD 2022-01-01 – 2022-12-31: 413000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lineage Cell Therapeutics, Inc. · 2022-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Capital Expenditure: 413000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 413000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000095017024027988/lctx-20231231.htm#1616156 Filing: 000095017024027988 The citation records this snapshot. The page link may show a newer release later.	USD 646,000 Calculation and evidence 1059000 − 413000 USD Exact free cash flow: 646000 USD 2022-01-01 – 2022-12-31: 1059000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 413000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lineage Cell Therapeutics, Inc. · 2022-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Free cash flow: 646000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1059000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000095017024027988/lctx-20231231.htm#1600600 Filing: 000095017024027988 Input fundies:CapitalExpenditure: 413000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000095017024027988/lctx-20231231.htm#1616156 Filing: 000095017024027988 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 21.49 million Exact value Exact value: -21486000 USD 2023-01-01 – 2023-12-31: -21486000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lineage Cell Therapeutics, Inc. · 2023-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Net Income: -21486000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21486000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000095017025036309/lctx-20241231.htm#1803775 Filing: 000095017025036309 The citation records this snapshot. The page link may show a newer release later.	−USD 28.57 million Exact value Exact value: -28566000 USD 2023-01-01 – 2023-12-31: -28566000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lineage Cell Therapeutics, Inc. · 2023-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Operating Cash Flow: -28566000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28566000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000095017025036309/lctx-20241231.htm#1866965 Filing: 000095017025036309 The citation records this snapshot. The page link may show a newer release later.	USD 674,000 Exact value Exact value: 674000 USD 2023-01-01 – 2023-12-31: 674000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lineage Cell Therapeutics, Inc. · 2023-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Capital Expenditure: 674000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 674000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000095017025036309/lctx-20241231.htm#1886461 Filing: 000095017025036309 The citation records this snapshot. The page link may show a newer release later.	−USD 29.24 million Calculation and evidence -28566000 − 674000 USD Exact free cash flow: -29240000 USD 2023-01-01 – 2023-12-31: -28566000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 674000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lineage Cell Therapeutics, Inc. · 2023-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Free cash flow: -29240000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28566000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000095017025036309/lctx-20241231.htm#1866965 Filing: 000095017025036309 Input fundies:CapitalExpenditure: 674000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000095017025036309/lctx-20241231.htm#1886461 Filing: 000095017025036309 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 18.61 million Exact value Exact value: -18609000 USD 2024-01-01 – 2024-12-31: -18609000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lineage Cell Therapeutics, Inc. · 2024-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Net Income: -18609000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18609000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2096687 Filing: 000119312526093992 The citation records this snapshot. The page link may show a newer release later.	−USD 23.09 million Exact value Exact value: -23092000 USD 2024-01-01 – 2024-12-31: -23092000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lineage Cell Therapeutics, Inc. · 2024-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Operating Cash Flow: -23092000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23092000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2167745 Filing: 000119312526093992 The citation records this snapshot. The page link may show a newer release later.	USD 565,000 Exact value Exact value: 565000 USD 2024-01-01 – 2024-12-31: 565000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lineage Cell Therapeutics, Inc. · 2024-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Capital Expenditure: 565000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 565000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2188553 Filing: 000119312526093992 The citation records this snapshot. The page link may show a newer release later.	−USD 23.66 million Calculation and evidence -23092000 − 565000 USD Exact free cash flow: -23657000 USD 2024-01-01 – 2024-12-31: -23092000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 565000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lineage Cell Therapeutics, Inc. · 2024-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Free cash flow: -23657000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23092000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2167745 Filing: 000119312526093992 Input fundies:CapitalExpenditure: 565000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2188553 Filing: 000119312526093992 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 63.53 million Exact value Exact value: -63533000 USD 2025-01-01 – 2025-12-31: -63533000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lineage Cell Therapeutics, Inc. · 2025-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Net Income: -63533000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -63533000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2094943 Filing: 000119312526093992 The citation records this snapshot. The page link may show a newer release later.	−USD 18.92 million Exact value Exact value: -18919000 USD 2025-01-01 – 2025-12-31: -18919000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lineage Cell Therapeutics, Inc. · 2025-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Operating Cash Flow: -18919000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18919000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2165877 Filing: 000119312526093992 The citation records this snapshot. The page link may show a newer release later.	USD 522,000 Exact value Exact value: 522000 USD 2025-01-01 – 2025-12-31: 522000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lineage Cell Therapeutics, Inc. · 2025-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Capital Expenditure: 522000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 522000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2186697 Filing: 000119312526093992 The citation records this snapshot. The page link may show a newer release later.	−USD 19.44 million Calculation and evidence -18919000 − 522000 USD Exact free cash flow: -19441000 USD 2025-01-01 – 2025-12-31: -18919000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 522000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lineage Cell Therapeutics, Inc. · 2025-12-31 Lineage Cell Therapeutics, Inc. (edgar:876343) Free cash flow: -19441000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:34:33Z Snapshot: ead6767f2ea6331e3d920530ba31a013b8269b7b2bb14f31d626162c36374932 Dimensions: Consolidated View: https://fundies.io/companies/edgar/876343?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18919000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2165877 Filing: 000119312526093992 Input fundies:CapitalExpenditure: 522000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/lctx-20251231.htm#2186697 Filing: 000119312526093992 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

163 filings · 5,681 latest values · 5,681 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000876343, 876343, BTX, LCTX, edgar:876343

Also known as BIOTIME INC, Lineage Cell Therapeutics, Inc., Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation